ReviewVascular pharmacology
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.
Review in Vascular pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Soluble receptor for advanced glycation end products (sRAGE) is associated with obesity rates: a systematic review and meta-analysis of cross-sectional study.BMC endocrine disorders · 2023Pooled it
- Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.Cardiovascular diabetology · 2015Trial
- Fibrillin-1 alleviates high glucose-induced fibroblast apoptosis and inflammation via autophagy activation.Nutrition & diabetes · 2026Article
- Insulin resistance as a modifiable contributor to breast cancer: mechanisms, biomarkers, and therapeutic implications.Discover oncology · 2026Review
- Increase in soluble RAGE following intensive insulin therapy is associated with β-cell functional improvement and glycemic remission in newly diagnosed type 2 diabetes.Journal of diabetes investigation · 2026Article
- Peripheral artery disease in diabetes.Frontiers in endocrinology · 2026Review
- Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".Biomarker insights · 2026Review
- Ferritinophagy Is Involved in the Advanced Glycation End Products-Induced Ferroptosis of Vascular Endothelial Cells in Diabetes Mellitus.Journal of cellular and molecular medicine · 2025Article
- Neutrophil percentage-to-albumin ratio mediates the association between life's crucial 9 with cardiorenal syndrome: a secondary data analysis from NHANES.BMC cardiovascular disorders · 2025Article
- Diabetic cardiomyopathy and COVID-19: intersecting pathways and amplified cardiovascular risk.Frontiers in pharmacology · 2025Review
- Bone Mineral Density is Negatively Associated with Risk of All-Cause and Cardiovascular Mortality among Adults with Type 2 Diabetes Mellitus: A Cross-sectional Study of the NHANES 2005-2010, 2013-2014.Reviews in cardiovascular medicine · 2024Article
- Hyperglycemia and Venous Thromboembolism.Diagnostics (Basel, Switzerland) · 2024Review
- Association of four differently processed diets with plasma and urine advanced glycation end products and serum soluble receptor for advanced glycation end products concentration in healthy dogs.Journal of animal physiology and animal nutrition · 2024Article
- Stem Cell-Based Tissue Engineering Approaches for Diabetic Foot Ulcer: a Review from Mechanism to Clinical Trial.Stem cell reviews and reports · 2024Review
- Prothrombotic status in COVID‑19 with diabetes mellitus (Review).Biomedical reports · 2023Review
- The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.Journal of experimental & clinical cancer research : CR · 2023Article
- Involvement of Intracellular TAGE and the TAGE-RAGE-ROS Axis in the Onset and Progression of NAFLD/NASH.Antioxidants (Basel, Switzerland) · 2023Review
- Blood-Borne Microparticles Are an Inflammatory Stimulus in Type 2 Diabetes Mellitus.ImmunoHorizons · 2023Article
- Therapeutic Potential of Phlorotannin-RichMarine drugs · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The multi-ligand receptor RAGE was discovered on account of its ability to bind and transduce the cell stress-provoking signals of advanced glycation endproducts (AGEs). The finding that RAGE also bound pro-inflammatory molecules set the stage for linking RAGE and inflammation to the pathogenesis of diabetic macro- and microvascular complications. In this review, we focus on the roles of RAGE and its ligands in diabetes complications. We recount the findings from mice, rats, swine and human subjects suggesting that RAGE action potently contributes to vascular, inflammatory and end-organ stress and damage in types 1 and 2 diabetes. We detail the efforts to track ligands and RAGE in human subjects with diabetes to address if this axis may be a biomarker reflective of the state of the diabetic complications. Lastly, we suggest specific strategies to tackle AGE-ligand-RAGE interactions as potential therapeutic targets for diabetes and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.